» Articles » PMID: 20547069

Surgical Treatment for Active Infective Prosthetic Valve Endocarditis: 22-year Single-centre Experience

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: We retrospectively analysed the profile and outcome of surgically treated patients with active infective prosthetic valve endocarditis (PVE) over a period of 22 years.

Methods: Between May 1986 and December 2008, a total of 1313 patients with active infective endocarditis (AIE) were operated on, 349 (26.6%) of them for PVE. Of these, 77 (22.1%) had to be operated upon due to early PVE (≤60 days, n=55 men, median age: 58 years) and 272 (77.9%) due to late PVE (n=200 men, median age: 63 years). A large proportion of patients were referred to our department with advanced endocarditis and in a condition of cardiac and pulmonary decompensation. A total of 226 (64.8%) patients developed periannular abscess. Operations consisted of 80 aortic valve, 45 mitral valve, 39 double valve and 165 aortic root replacements, 134 of them with a homograft. Perioperative characteristics, probability of survival, freedom from recurrence and predictors for hospital mortality were analysed. Follow-up (maximum: 19.4 years) was completed in 96.3% (total: 1118 patient-years).

Results: There was high early and late mortality. Overall in-hospital mortality was 28.4% (99/349). The 30-day, 1-, 5- and 10-year survival for the whole PVE study population was 71.4 ± 2.4%, 58.7 ± 2.7%, 44.5 ± 3% and 31.7 ± 3.5% with no significant differences between the early and late PVE patients: 67 ± 5.4%, 55.9 ± 5.8%, 49.4 ± 6.2% and 29.7 ± 7.6%, compared to 72.4 ± 3%, 60 ± 3%, 43.5 ± 3.3% and 31.1 ± 3.8% (p=0.93). Predictors of early mortality were mechanical support (risk ratio (RR): 4.3), emergency operation (RR: 2.1), preoperative high doses of catecholamines (RR: 1.8), mitral valve replacement (RR: 1.5) and age at operation (RR: 1.1). Freedom from re-operation due to recurrent endocarditis at 10 years was 85.8 ± 5.6% for early PVE compared to 92.1 ± 2.3% for late PVE patients (p=0.17). Staphylococcus aureus (S. aureus) (18.1%) was the most frequent causative micro-organism.

Conclusions: Surgery for active infective PVE continues to be challenging. It not only carries a high in-hospital mortality but is also associated with a high long-term mortality risk. Early PVE patients were in a more severe condition than late PVE patients. Preoperative status, complications and co-morbidity of PVE patients strongly predict early outcome. Because of the potential risk of late complications, PVE patients need close clinical follow-up.

Citing Articles

Mechanical versus Biological Valve Prostheses for Infective Endocarditis Presenting with Stroke.

Kahrovic A, Angleitner P, Herkner H, Werner P, Andreeva A, Poschner T J Clin Med. 2024; 13(19).

PMID: 39407772 PMC: 11477093. DOI: 10.3390/jcm13195712.


Three Decades of Experience with Aortic Prosthetic Valve Endocarditis.

Galeone A, Gardellini J, Trojan D, Di Nicola V, Di Gaetano R, Faggian G J Cardiovasc Dev Dis. 2023; 10(8).

PMID: 37623351 PMC: 10456059. DOI: 10.3390/jcdd10080338.


How to counteract the lack of donor tissue in cardiac surgery? Initial experiences with a newly established homograft procurement program.

Schmiady M, Jashari R, Lenherr R, Regenscheit S, Hitendu D, Wendt M Cell Tissue Bank. 2023; 25(1):1-10.

PMID: 37097383 PMC: 10126547. DOI: 10.1007/s10561-023-10087-z.


Cryopreserved human heart valve allografts: a ten-year single centre experience.

Skific M, Golemovic M, Safradin I, duric Z, Biocina B, Golubic Cepulic B Cell Tissue Bank. 2022; 24(2):401-416.

PMID: 36222968 PMC: 9555264. DOI: 10.1007/s10561-022-10043-3.


Early surgical intervention in culture-negative endocarditis of the aortic valve complicated by abscess in an infant: A case report.

Yang Y, Si F, Chen T, Fan L, Lu Y, Jin M World J Clin Cases. 2022; 9(35):11016-11023.

PMID: 35047612 PMC: 8678864. DOI: 10.12998/wjcc.v9.i35.11016.